Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fed Conditions
Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
The objective of this single-dose, open-label, randomized, two-period crossover study was to
compare the rate of absorption and oral bioavailability of a test formulation of morphine
sulfate 200 mg sustained-release capsules manufactured by Alpharma Branded Products Division
Inc. to an equivalent oral dose of the commercially available reference product, KADIAN 2 x
100 mg capsules manufactured by Alpharma Branded Products Division Inc. when administered
under fed conditions.